Zhixia X. Qiu

Jiangsu Key Laboratory Of Drug Design And Optimization, P.R. China
Nanjing, 211198, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability.

Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability.

Journal: Journal of medicinal chemistry

Published: March 20, 2026

Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity.

Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity.

Journal: Future medicinal chemistry

Published: March 12, 2026

DB-2B, a Novel and Selective STAT3 Inhibitor Inhibits Colorectal Cancer Progression In Vitro and In Vivo.

DB-2B, a Novel and Selective STAT3 Inhibitor Inhibits Colorectal Cancer Progression In Vitro and In Vivo.

Journal: Biomolecules

Published: December 17, 2025

Design, synthesis, and pharmacological evaluation of novel isoindoline-based HPK1 degraders.

Design, synthesis, and pharmacological evaluation of novel isoindoline-based HPK1 degraders.

Journal: European journal of medicinal chemistry

Published: October 01, 2025

Development and validation of UPLC-MS/MS method for pharmacokinetics and tissue distribution of Tylvalosin and its bioactive metabolites in swine.

Development and validation of UPLC-MS/MS method for pharmacokinetics and tissue distribution of Tylvalosin and its bioactive metabolites in swine.

Journal: Veterinary research communications

Published: September 23, 2025

Discovery of Tricyclic Derivative as Novel and Potent Respiratory Syncytial Virus Fusion Glycoprotein Inhibitor with an Improved Pharmacokinetic Profile.

Discovery of Tricyclic Derivative as Novel and Potent Respiratory Syncytial Virus Fusion Glycoprotein Inhibitor with an Improved Pharmacokinetic Profile.

Journal: Journal of medicinal chemistry

Published: September 11, 2025

Integrated pharmacokinetic properties and tissue distribution of Corydalis saxicola Bunting total alkaloids in HFHCD-induced mice: Implications for pharmacokinetic variability in MASH treatment.

Integrated pharmacokinetic properties and tissue distribution of Corydalis saxicola Bunting total alkaloids in HFHCD-induced mice: Implications for pharmacokinetic variability in MASH treatment.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: June 13, 2025

Design and Discovery of Preclinical Candidate LYG-409 as a Highly Potent and Selective GSPT1 Molecular Glue Degraders.

Design and Discovery of Preclinical Candidate LYG-409 as a Highly Potent and Selective GSPT1 Molecular Glue Degraders.

Journal: Journal of medicinal chemistry

Published: January 24, 2025

Dual inhibition of hepatic ACLY and ACSS2: A synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement.

Dual inhibition of hepatic ACLY and ACSS2: A synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement.

Journal: Pharmacological research

Published: January 14, 2025

Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib-Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency.

Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib-Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: September 18, 2024

Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia.

Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia.

Journal: Journal of medicinal chemistry

Published: April 04, 2024

Structure-Guided Discovery of Potent and Selective CLK2 Inhibitors for the Treatment of Knee Osteoarthritis.

Structure-Guided Discovery of Potent and Selective CLK2 Inhibitors for the Treatment of Knee Osteoarthritis.

Journal: Journal of medicinal chemistry

Published: March 19, 2024

Showing 1-12 of 53

Last Updated: 09/26/2026